$0.00
Register for Meetings
“In The News” & “Cardiovascular Marketplace” Content Access
Listen to Podcasts
Watch On-Demand Content
CardioTube Access
Access to Recorded Live Broadcasts from CRTvirtual Meetings, DMV, & Cath Conference
Access Recorded Interviews
Download PPT Slide Decks
$450 Annually
Complimentary subscription to electronic version of the CRM Journal
Access to CRT Meeting Registration Discounts
CRT Premium Content, including on-demand videos and presentation downloads
Nathan Gray, CRTonline.org
Treatment with the Factor XI activity inhibitor asundexian results in significantly lower rates of bleeding compared with apixaban and is well-tolerated, according to new data from the Phase 2 dose-finding PACIFIC-AF trial.
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details